Novartis Announces FDA and EMA Filing Acceptance of Siponimod for Secondary Progressive Multiple Sclerosis (SPMS)

Basel, October 08, 2018 - Novartis today announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company's New Drug Application (NDA) and Marketing Authorization Application (MAA)... (Source: Drugs.com - New Drug Applications)


Read full article on medworm.com




 
 
 

Follow Us on Twitter

Follow Us On Twitter - Image